Literature DB >> 35368601

Use of Gadolinium-Based Contrast Agents in Patients with Severe Renal Impairment. Absence of Risk Versus Caution: A Nephrologist's Perspective.

Michael R Rudnick1, Ihab M Wahba1,2, Amanda K Leonberg-Yoo1.   

Abstract

Entities:  

Keywords:  chronic kidney disease; clinical nephrology; gadolinium-based contrast agents; magnetic resonance imaging; nephrogenic systemic fibrosis

Mesh：

Substances：

Year:  2020        PMID： 35368601      PMCID： PMC8809313          DOI： 10.34067/KID.0003022020

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  8 in total

1.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

2.  Gadolinium deposition disease: Initial description of a disease that has been around for a while.

Authors:  Richard C Semelka; Joana Ramalho; Ami Vakharia; Mamdoh AlObaidy; Lauren M Burke; Michael Jay; Miguel Ramalho
Journal:  Magn Reson Imaging       Date:  2016-08-13       Impact factor: 2.546

3.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients.

Authors:  S E Cowper; H S Robin; S M Steinberg; L D Su; S Gupta; P E LeBoit
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

4.  Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.

Authors:  Sean A Woolen; Prasad R Shankar; Joel J Gagnier; Mark P MacEachern; Lisa Singer; Matthew S Davenport
Journal:  JAMA Intern Med       Date:  2020-02-01       Impact factor: 21.873

5.  Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists.

Authors:  Nicola Schieda; Pejman Jabehdar Maralani; Casey Hurrell; Anne K Tsampalieros; Swapnil Hiremath
Journal:  Can Assoc Radiol J       Date:  2019-06-27       Impact factor: 2.248

Review 6.  Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution.

Authors:  Catherine Do; Joshua DeAguero; Adrian Brearley; Xochitl Trejo; Tamara Howard; G Patricia Escobar; Brent Wagner
Journal:  Kidney360       Date:  2020-06-25

7.  The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review.

Authors:  Cyprian Olchowy; Kamil Cebulski; Mateusz Łasecki; Radosław Chaber; Anna Olchowy; Krzysztof Kałwak; Urszula Zaleska-Dorobisz
Journal:  PLoS One       Date:  2017-02-10       Impact factor: 3.240

8.  10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016.

Authors:  Jan Endrikat; Susan Dohanish; Nicolas Schleyer; Susanne Schwenke; Sheela Agarwal; Thomas Balzer
Journal:  Invest Radiol       Date:  2018-09       Impact factor: 6.016
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.